The Charcot Lecture | Beating MS: A story of B cells, with twists and turns

Multiple Sclerosis Journal

Volumn 21, Issue 1, 2015, Pages 8-21

  Hauser, Stephen L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Charcot Lecture; Multiple sclerosis

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; PLACEBO; RITUXIMAB;

B LYMPHOCYTE; BLOOD; BLOOD BRAIN BARRIER; CELL EXPANSION; CELL MATURATION; CEREBROSPINAL FLUID; CLINICAL RESEARCH; DISEASE ACTIVITY; DISEASE MODEL; HUMAN; HUMORAL IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CELL; REVIEW; T LYMPHOCYTE; TISSUE INJURY; ADAPTIVE IMMUNITY; ARTICLE; B CELL LYMPHOMA; DISEASE COURSE; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY;

B-LYMPHOCYTES; HUMANS; MULTIPLE SCLEROSIS;

EID: 84922879643     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514561911     Document Type: Review

References (54)

1. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
2. Genain CP and Hauser SL. Creation of a model for multiple sclerosis in Callithrix jacchus marmosets. J Mol Med (Berl) 1997; 75: 187-197.
3. Massacesi L, Genain CP, Lee-Parritz D, et al. Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis. Ann Neurol 1995; 37: 519-530.
4. Genain CP and Hauser SL. Allergic encephalomyelitis in common marmosets: Pathogenesis of a multiple sclerosis-like lesion. Methods 1996; 10: 420-434.
5. Prineas JW and Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology 1978; 28: 68-75.
6. Genain CP, Nguyen MH, Letvin NL, et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 1995; 96: 2966- 2974.
7. Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996; 274: 2054-2056.
8. Appel SH and Bornstein MB. The application of tissue culture to the study of experimental allergic encephalomyelitis. II. Serum factors responsible for demyelination. J Exp Med 1964; 119: 303-312.
9. Lorentzen JC, Issazadeh S, Storch M, et al. Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 1995; 63: 193-205.
10. Linington C, Berger T, Perry L, et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 1993; 23: 1364-1372.
11. Genain CP, Cannella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 170-175.
12. Raine CS, Cannella B, Hauser SL, et al. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen-specific antibody mediation. Ann Neurol 1999; 46: 144-160.
13. Hauser SL, Fosburg M, Kevy S, et al. Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis. Prog Clin Biol Res 1982; 106: 239-254.
14. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173-180.
15. Mattson DH, Roos RP and Arnason BG. Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature 1980; 287: 335-337.
16. von Budingen HC, Bar-Or A and Zamvil SS. B cells in multiple sclerosis: Connecting the dots. Curr Opin Immunol 2011; 23: 713-720.
17. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67: 452-461.
18. Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62: 1755-1762.
19. Silverman GJ and Boyle DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: The B-cell roadblock hypothesis. Immunol Rev 2008; 223: 175-185.
20. Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, doubleblind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012; 64: 350-359.
21. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010; 49: 1683-1693.
22. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378: 1779-1787.
23. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092-6099.
24. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 62-74.
25. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180: 63-70.
26. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67: 707-714.
27. Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62: 258-264.
28. Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 2014; 193: 580-586.
29. Molnarfi N, Schulze-Topphoff U, Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013; 210: 2921-2937.
30. Lyons JA, San M, Happ MP, et al. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 1999; 29: 3432-3439.
31. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-950.
32. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010; 68: 369-383.
33. Kappos L, Hartung HP, Freedman MS, et al. Atacicept in multiple sclerosis (ATAMS): A randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 2014; 13: 353-363.
34. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353-1360.
35. Farh KK, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. Epub ahead of print 29 October 2014.
36. Kinnunen T, Chamberlain N, Morbach H, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest 2013; 123: 2737-2741.
37. Pieper K, Grimbacher B and Eibel H. B-cell biology and development. J Allergy Clin Immunol 2013; 131: 959-971.
38. Neuberger MS. Antibody diversification by somatic mutation: From Burnet onwards. Immunol Cell Biol 2008; 86: 124-132.
39. Baranzini SE, Mudge J, van Velkinburgh JC, et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010; 464: 1351-1356.
40. Glanville J, Kuo TC, von Budingen HC, et al. Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation. Proc Natl Acad Sci U S A 2011; 108: 20066-20071.
41. von Budingen HC, Kuo TC, Sirota M, et al. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest 2012; 122: 4533-4543.
42. Palanichamy A, Apeltsin L, Kuo TC, et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med 2014; 6: 248ra106.
43. Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008; 14: 688-693.
44. Bankoti J, Apeltsin L, Hauser SL, et al. In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol 2014; 75: 266-276.
45. Stern JN, Yaari G, Vander Heiden JA, et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med 2014; 6: 248ra107.
46. Owens GP, Winges KM, Ritchie AM, et al. VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J Immunol 2007; 179: 6343-6351.
47. Owens GP, Kraus H, Burgoon MP, et al. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998; 43: 236-243.
48. Hauser SL, Chan JR and Oksenberg JR. Multiple sclerosis: Prospects and promise. Ann Neurol 2013; 74: 317-327.
49. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089-1104.
50. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized doubleblind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
51. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: Results of the GAUDI study (BO21000). Blood 2013; 122: 1137-1143.
52. Puri KD, Di Paolo JA and Gold MR. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. Int Rev Immunol 2013; 32: 397-427.
53. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-223.
54. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.